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Background: Monoclonal antibody therapy has an important role to play as a post-exposure prophylactic and
therapeutic for the treatment of viral infections, including emerging infections. For example, several patients of the
present Ebola virus outbreak in West Africa were treated with ZMapp, a cocktail of three monoclonal antibodies
which are expressed in Nicotiana benthamiana.
Discussion: The majority of monoclonal antibodies in clinical use are expressed in mammalian cell lines which offer
native folding and glycosylation of the expressed antibody. Monoclonal antibody expression in vegetal systems
offers advantages over expression in mammalian cell lines, including improved potential for scale up and reduced
costs. In this paper, I highlight the advantages of an upcoming protozoal system for the expression of recombinant
antibody formats. Leishmania tarentolae offers a robust, economical expression of proteins with mammalian
glycosylation patterns expressed in stable cell lines and grown in suspension culture. Several advantages of this
system make it particularly suited for use in developing contexts.
Summary: Given the potential importance of monoclonal antibody therapy in the containment of emerging viral
infections, novel and alternative strategies to improve production must be explored.
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Nations.Background
Monoclonal antibodies (mAbs) are used in wide range of
contexts, including biomedical research and in the diag-
nosis and treatment of diseases. In recent decades, much
research has been conducted into the development of
mAbs as therapeutics for cancer [1], autoimmune condi-
tions [2] and infectious diseases [3]. The majority of
mAbs in clinical use are human, chimeric or humanised
[4], and these molecules retain the native antibody struc-
ture, containing both the fragment antigen-binding (Fab)
and fragment crystallisable (Fc) domains [5]. The FcCorrespondence: jdj24@cam.ac.uk
Division of Virology, Department of Pathology, University of Cambridge,
Tennis Court Road, Cambridge CB2 1QP, UK
© 2015 Jones; licensee BioMed Central. This is
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.domain determines the range of biological effects an
antibody isotype may have. For example, the antibodies
of the IgG1 isotype are better opsonins than those of the
IgG4 isotype [6]. The advantages of mAb therapy in-
clude low toxicity, high specificity and versatility, with
the range of biological effects dependent upon the Fc re-
gion. Functions of mAbs reflect the functions of native
antibody isotypes and can include pathogen opsonisa-
tion, complement activation, antibody-dependent cell
cytotoxicity and virus neutralisation.
In recent years, however, many new recombinant anti-
body fragment formats have been developed which lack
the Fc domain [7]. These include single-chain fragment
variable molecules (scFvs) in which a flexible amino
acid linker joins two variable domains, as illustrated in
Figure 1 [8]. Instead of using the biological functions
imparted by the Fc domain, antibody fragment formats
are used when only antigen binding is required, for ex-
ample in diagnostic assays, drug delivery or virus neutral-
isation [9,10]. A recombinant bivalent antibody formatan Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The structures of native IgG, scFv and bivalent scFv-Fc fusion molecules. Red and green: variable domains; blue: constant domains; brown:
disulphide bonds; orange: artificial peptide linker.
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fusion of an scFv to an Fc domain (see Figure 1) [11].
These recombinant bivalent molecules have improved af-
finity and serum half-life relative to scFvs [12], and have
demonstrated efficacy in mice against Venezuelan equine
encephalitis virus [13].
Antibody therapy as a treatment for infectious disease
has its origins in the ‘serum therapy’ treatments of the
1890s, and today mAbs are licensed for passive anti-
body therapy to treat a range of viral infections includ-
ing respiratory syncytial virus, hepatitis A, hepatitis B
and varicella-zoster virus (reviewed in [14]). Neutralis-
ing mAbs have an important role to play in the treat-
ment of emerging infections for which vaccines are
presently unavailable. For example, in the 2010 out-
break of Hendra virus in Queensland, Australia, two
patients were treated with neutralising mAbs specific
for the henipavirus G envelope glycoprotein receptor
binding domain [15,16]. More recently, a cocktail of
neutralising mAbs specific for Ebola virus (EBOV),
ZMapp, has shown promising results in non-human
primates (NHPs) [17], and was used in the treatment of
several patients of the current EBOV outbreak in West
Africa [18]. Therefore, where vaccination is immuno-
logically challenging to develop, or an efficacious vac-
cine is yet to be produced, as in the case of EBOV,
mAbs offer an invaluable therapeutic alternative. This
article will discuss the importance of considering a sus-
tainable expression system for mAbs and will highlight
a protozoal expression system which may be particu-
larly suited to use in developing contexts.Discussion
At the time of writing (December 2014), the total num-
ber of cases recorded in the current EBOV outbreak in
West Africa has reached an estimated 18,000, with some
6,400 deaths. Given the severity of the outbreak, a small
number of patients were treated with ZMapp, a cocktail
of three mAbs, but the limited supply of ZMapp was
soon exhausted [18]. Although only given to a small
number of patients, the efficacy of ZMapp has been
demonstrated in NHPs, and the antibodies which com-
prise the cocktail are presently expressed in Nicotiana
benthamiana [17]. While further safety and efficacy test-
ing of ZMapp is required before it is routinely used to
treat EBOV, the nature of the expression vector must
also be considered. Foremost amongst the requirements
of a system suitable for the expression of mAbs are yield,
cost effectiveness, potential for scale up, ease of purifica-
tion, low risk of hazardous viral contamination and na-
tive folding and glycosylation of the expressed antibody
[11,19]. Differences between the glycosylation profiles of
administered mAbs and the cells of the recipient are
known to increase the immunogenicity of the expressed
mAb [20,21]. Moreover, subtle alterations in the glyco-
sylation of the Fc region are known to alter the antibody
effector functions [22].
The requirement for a native glycosylation profile to
minimise potential immunogenicity remains a key rea-
son why the majority of currently approved therapeutic
mAbs are expressed in mammalian cell lines, despite
relatively high production costs which are not signifi-
cantly mitigated by scaling up [11]. However, the
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benthamiana has been addressed by the use of ribo-
nucleic acid (RNA) interference technology to engineer
plants with a humanised glycosylation profile [23]. Re-
search has also been undertaken into the humanising
of well-characterised bacterial expression systems. For
example, the recent transfer of a Campylobacter N-
linked glycosylation cassette into Escherichia coli raises
the possibility of the humanisation of bacterial expres-
sion systems [24]. However, bacterial expression sys-
tems are typically unsuitable for native mAb expression
as they lack both the sophisticated folding apparatus
and post-translational modifications required for native
mAb production. Instead, bacterial systems have been
widely used for the expression of a variety of recombinant
antibody formats, including Fab and scFvs [11]. Import-
antly, recent research has suggested that a protozoal ex-
pression system may be able to express recombinant
antibody formats with a mammalian glycosylation pattern.
The non-pathogenic eukaryotic protozoan Leishmania
tarentolae, whose genome was sequenced in 2012 [25],
has been used to investigate RNA editing [26], gene
amplification [27] and as a vaccine candidate for the dis-
ease leishmaniasis [28]. Since its description as an ex-
pression system in 2002 [29], L. tarentolae has found a
range of applications, including the expression of human
soluble amyloid precursor protein alpha, a cleavage
product of amyloid precursor protein, the aetiological
agent of Alzheimer’s disease [30]. The advantages of the
L. tarentolae expression system include facile handling
of cultures, an optimal culture temperature of 26°C,
rapid growth rate (with a doubling time of approxi-
mately six hours in agitated culture), high cell densities
(up to 109 cells/ml), promising potential for scale up, the
ability to produce stable cell lines and a complete
eukaryotic folding and post-translational modification
machinery, including a mammalian glycosylation profile
[29,31-33]. Recent research has demonstrated the use of
L. tarentolae to express scFvs fused to a rabbit Fc region,
which resulted in a recombinant bivalent antibody for-
mat similar to the native antibody structure [34]. The
authors also demonstrated the ease of purification of the
secreted scFv-Fc fusions from the culture media using
one-step affinity purification. As mentioned above, scFv-
Fc fusions have enhanced affinity, a reduced propensity
to aggregate and significant improvements in serum
half-life relative to scFvs [12]. Therefore, L. tarentolae
represents a eukaryotic expression platform with the po-
tential to produce high yields of neutralising scFv-Fc fu-
sion proteins.
As we have seen with the present EBOV outbreak in
West Africa, neutralising mAbs have the potential to play
a key role in the containment of emerging viral infections.
In the absence of a vaccine, mAbs can be effectivelyemployed as a post-exposure prophylactic, while mAbs
may continue to be used alongside a vaccine as a post-
exposure therapeutic. Therefore, there is a need for cheap
and scalable expression systems which can be rapidly
employed to express high yields of recombinant antibody
formats. The majority of mAbs in clinical use are
expressed in mammalian cell lines, typically Chinese ham-
ster ovary cells. The advantages of expression in such
mammalian cell lines include native post-translational
modifications, the production of stable cell lines and
large- scale suspension culture [35]. Recombinant mAb
expression in N. benthamiana offers advantages over
mammalian cell lines, principally significantly lower costs,
more efficient potential for scale up and, in engineered
plants, a more uniform humanised glycosylation profile
[11,22]. However, the L. tarentolae expression platform
must be developed alongside these systems as a potential
alternative for the expression of neutralising mAbs, in-
cluding ZMapp. This platform offers a robust and cost-
effective alternative, with the potential for high yields of
easily purified recombinant antibody formats with mam-
malian glycosylation patterns expressed in stable cell lines
grown in suspension. If we are to envisage mAbs as a key
part of the containment of emerging viral infections, we
must interrogate the best strategies to rapidly and cheaply
produce sufficient quantities.
Moreover, several features of L. tarentolae make it par-
ticularly suited to recombinant antibody production in
developing contexts; in particular, the ease of handling,
low production costs and ease of purification. As a trop-
ical protozoan with an optimal growth temperature of
26°C, the potential for L. tarentolae to be cultured at
ambient temperature in tropical developing contexts
should be evaluated, as ambient culture would signifi-
cantly reduce production costs. The potential for ambient
culture may be further enhanced by the development of
strains with greater tolerance for a range of temperatures
to reflect the variation in daily temperatures. While the
majority of industrial recombinant protein expression oc-
curs in developed nations, in the long term, the involve-
ment of developing nations in the production of mAbs
could bring many benefits to the containment of emerging
infections and the nations involved. However, I acknow-
ledge that there are potential legal and regulatory obstacles
to the production of mAbs in developing contexts, includ-
ing issues of intellectual property and regulation. Ultim-
ately, the demand in developed countries for mAb therapy
for the treatment of conditions including cancer and auto-
immunity will continue to rise, making the pursuit of al-
ternative, more economical mAb expression systems likely
to benefit pharmaceutical companies marketing their
products in developed contexts. The production of mAbs
in developing contexts would bring associated capacity
building that would also deliver much-needed jobs and
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purify mAbs at the frontline of emerging viral infections
could significantly aid containment, and reduce both the
cold chain to affected regions and logistical obstacles to
the dissemination of treatment.
Summary
In this paper, I have used the recent EBOV outbreak in
West Africa to illustrate the need to continue to develop
alternative, sustainable, strategies for mAb expression.
Platforms for mAb expression must offer sustainable,
rapid, cost-effective yields of easily purified recombinant
mAb formats with a mammalian glycosylation pattern
[11,19]. The majority of mAbs in clinical use are
expressed in mammalian cell lines, which entail high
production costs not significantly mitigated by scale up.
Here I have sought to highlight the potential value of
the developing L. tarentolae expression platform. In par-
ticular, the recent expression of an scFv-Fc fusion in L.
tarentolae raises the possibility that this platform could
offer sustainable, cost-effective, production of recombin-
ant mAb formats with mammalian a glycosylation pat-
tern [34]. The refinement of strategies for rapid and
sustainable expression of mAbs must consider L. tarento-
lae alongside strategies already in use, such as N.
benthamiana. Moreover, the L. tarentolae system is suited
to use in developing contexts, with the long-term involve-
ment of developing nations in mAb production being
beneficial to the containment of emerging viral diseases.
Given that mAbs have the potential to play a key role in
the containment of emerging viral infections, alternative
strategies to improve the production of mAbs, including
in developing contexts, must be carefully considered.
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